Patents Assigned to Medtronic Ireland Manufacturing Unlimited Company
-
Patent number: 11974804Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: GrantFiled: July 1, 2021Date of Patent: May 7, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Denise Zarins, Hanson Gifford, III, Mark E. Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Patent number: 11963718Abstract: Microwave catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a microwave transmission element to a renal artery via an intravascular path. Renal neuromodulation may be achieved via dielectric heating in the presence of microwave irradiation that modulates neural fibers that contribute to renal function or alters vascular structures that feed or perfuse the neural fibers.Type: GrantFiled: May 19, 2021Date of Patent: April 23, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Karun D. Naga, Roman Turovskiy, Denise Zarins, Mark Gelfand, Arye Rosen
-
Patent number: 11963714Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.Type: GrantFiled: June 14, 2021Date of Patent: April 23, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Mark E. Deem, Hanson S. Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
-
Patent number: 11950826Abstract: Catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present technology, for example, is directed to a treatment device having a direct heating element configured to be delivered to a renal blood vessel. The treatment device is selectively transformable between a delivery or low-profile state and a deployed state. The direct heating element is housed within an occlusion element which is sized and shaped so that the direct heating element contacts an interior wall of the occlusion element, an outer wall of which is simultaneously in contact with the inner wall of a renal blood vessel when the treatment assembly is in the deployed state. The direct heating element is configured to apply thermal energy to heat neural fibers that contribute to renal function.Type: GrantFiled: June 24, 2020Date of Patent: April 9, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventor: Roman Turovskiy
-
Patent number: 11890047Abstract: Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.Type: GrantFiled: May 19, 2021Date of Patent: February 6, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Gabriel Lazarus, Douglas A. Hettrick
-
Patent number: 11883087Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including selectively neuromodulating afferent or efferent renal nerves. One or more measurable physiological parameters corresponding to systemic sympathetic overactivity or hyperactivity in the patient can thereby be reduced. Selectively neuromodulating afferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a renal pelvis. This can include, for example, neuromodulating via fluid within the renal pelvis. Selectively neuromodulating efferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a portion of a renal artery or a renal branch artery proximate a renal parenchyma. This can include, for example, neuromodulating via a therapeutic element within the portion of the renal artery or the renal branch artery.Type: GrantFiled: September 30, 2022Date of Patent: January 30, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Stefan Tunev, Julie Trudel
-
Patent number: 11865343Abstract: Methods for treating post-traumatic stress disorder (PTSD) and/or for reducing a risk associated with developing PTSD in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with PTSD as well as an increased risk of developing PTSD following a traumatic event. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a PTSD status in the patient. Other aspects are directed to reducing a likelihood of developing PTSD in patients presenting one or more PTSD risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's PTSD status or risk of developing PTSD. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.Type: GrantFiled: November 1, 2021Date of Patent: January 9, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Marcia Gallagher, Douglas A. Hettrick
-
Patent number: 11864904Abstract: Systems and methods for measuring the magnetic fields generated by renal nerves before and/or after neuromodulation therapy are disclosed herein. One method for measuring the magnetic field of target nerves during a neuromodulation procedure includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient near the target nerves, and detecting a measurement of the magnetic field generated by the target nerves. The method can further include determining, based on the measurement of the magnetic field, a location of the target nerves, a location of ablation at the target nerves, and/or a percentage the target nerves were ablated by delivered neuromodulation energy.Type: GrantFiled: January 12, 2022Date of Patent: January 9, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Abhijeet Dubhashi, Douglas Hettrick, Guo Xu
-
Patent number: 11857249Abstract: The present disclosure relates to devices, systems and methods providing evaluation and feedback to an operator of a device providing neuromodulation treatment, such as modulation of renal nerves of a human patient. In one embodiment, for example, a system monitors parameters or values generated before treatment. Feedback provided to an operator is based on the monitored values and relates to an assessment of various electrical properties associated with an electrode carried by a catheter. The electrode measures an electrical property of biological material making contact with the electrode while deploying the electrode, the electrical property being dependent on a ratio of a wall-interface area to a fluid-interface area.Type: GrantFiled: February 26, 2020Date of Patent: January 2, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Vincent Ku, Sowmya Ballakur, Jignesh Shah
-
Patent number: 11844568Abstract: Systems and methods for neuromodulation therapy are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, positioning a plurality of reference electrodes at the skin of a human patient and intravascularly positioning a plurality of ablation electrodes within a blood vessel lumen at a treatment site. The method can include obtaining impedance measurements between different combinations of the reference electrodes and the ablation electrodes and, based on the impedance measurements, identifying two or more electrode groups for treatment, where at least two of the electrode groups include a different one of the reference electrodes and a different one of the ablation electrodes.Type: GrantFiled: April 6, 2022Date of Patent: December 19, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Douglas A. Hettrick, Julie Trudel, Paul Coates, Robert J. Melder, Stefan S. Tunev, Martin Rothman, Sean Salmon
-
Patent number: 11844558Abstract: Methods for treating eating disorders and for reducing a risk associated with developing an eating disorder in patients via therapeutic renal neuromodulation and associated systems. Renal sympathetic nerve activity can be attenuated to improve a patient's eating disorder status or risk of developing an eating disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to modulate the renal sympathetic nerve.Type: GrantFiled: July 27, 2022Date of Patent: December 19, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Gabriel Lazarus, Douglas A. Hettrick
-
Patent number: 11801085Abstract: Methods and system are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues. In some embodiments, thermally-induced renal neuromodulation is achieved via delivery of a pulsed thermal therapy.Type: GrantFiled: July 24, 2020Date of Patent: October 31, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Andrew Wu, Benjamin J. Clark, Erik Thai, Nicolas Zadno, Denise Zarins
-
Patent number: 11779392Abstract: Provided herein are methods, systems, and devices for increasing heat shock protein expression and treating conditions for which increased heat shock protein expression is expected to be beneficial using thermal ablation.Type: GrantFiled: May 3, 2021Date of Patent: October 10, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Ayala Hezi-Yamit, Susan Edwards, Carol Sullivan
-
Patent number: 11717343Abstract: Systems and methods for neuromodulation therapy are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, intravascularly positioning a plurality of ablation electrodes within a blood vessel lumen at a treatment site. The method can include analyzing a renal neuromodulation target site of a patient to obtain patient-specific data related to the renal neuromodulation target site, and based on the patient specific data, delivering neuromodulation treatment to the patient via one or more of the ablation electrodes.Type: GrantFiled: April 27, 2018Date of Patent: August 8, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Paul J. Coates, Robert J. Melder
-
Patent number: 11707220Abstract: Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.Type: GrantFiled: May 28, 2020Date of Patent: July 25, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Douglas Hettrick, Shantanu Sarkar
-
Patent number: 11672456Abstract: Example devices, systems, and techniques predict renal denervation efficacy for reducing hypertension in a patient based on pulse information. For example, a system may include processing circuitry configured to obtain pulse information representative of pulses from both wrists of a patient, obtain a plurality of values representative of respective patient metrics for the patient, and apply the pulse information and the plurality of values to a deep learning model trained to represent a relationship of the pulse information and the patient metrics to an efficacy of renal denervation in reducing hypertension. In some examples, responsive to applying the pulse information and the plurality of values to the deep learning model, the processing circuitry obtains, from the deep learning model, a score indicative of renal denervation efficacy in reducing hypertension for the patient, and generates a graphical user interface comprising a graphical representation of the score for the patient.Type: GrantFiled: April 25, 2019Date of Patent: June 13, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventor: Abhijeet Dubhashi
-
Patent number: 11673006Abstract: Catheter-based devices and associated methods for immune system neuromodulation of human patients are disclosed herein. One aspect of the present technology is directed to methods of treating a human patient diagnosed with an immune system condition. The methods can include intravascularly positioning a neuromodulation catheter within a blood vessel proximate to neural fibers innervating an immune system organ of the patient. The method also includes reducing sympathetic neural activity in the patient by delivering energy to the neural fibers innervating the immune system organ via the neuromodulation catheter. Reducing sympathetic neural activity improves a measurable physiological parameter corresponding to the immune system condition of the patient.Type: GrantFiled: September 11, 2020Date of Patent: June 13, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Paul Sobotka, Neil Barman
-
Patent number: 11666380Abstract: Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.Type: GrantFiled: March 16, 2020Date of Patent: June 6, 2023Assignee: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANYInventors: Andrew Wu, Benjamin J. Clark, Denise Zarins, Erik Thai
-
Patent number: 11607275Abstract: Methods, systems, devices, assemblies and apparatuses for treatment of hypertension in a patient using renal denervation. The therapeutic assembly includes an energy delivery element. The energy delivery element is configured to provide renal denervation energy to a nerve within a blood vessel of a patient. The therapeutic assembly includes a controller. The controller is coupled to the energy delivery element. The controller is configured to determine that the hypertension in the patient is orthostatic. The controller is configured to apply renal denervation energy to the patient using the energy delivery element.Type: GrantFiled: May 18, 2020Date of Patent: March 21, 2023Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Sandeep Brar, Martin Fahy, Vanessa Debruin, Colleen Gilbert